A client with polycystic kidney disease is prescribed the medication Tolvaptan. What should the nurse include when educating the client about this medication.
This medication increases the glomerular filtration rate.
This medication will prevent you from eventually needing a kidney transplant.
This medication slows the growth of renal cysts.
This medication can cause hyponatremia.
The Correct Answer is C
A. Tolvaptan does not increase the glomerular filtration rate. It actually works by blocking the action of a hormone that causes the kidneys to retain water, leading to increased urine output.
B. While Tolvaptan can slow the progression of polycystic kidney disease (PKD) and delay the need for dialysis or transplant, it does not guarantee prevention of these outcomes.
C. Tolvaptan is used to slow the growth of kidney cysts in patients with PKD.
D. Hyponatremia is a common side effect of Tolvaptan due to increased water loss through urine. However, this is not the primary role.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is B
Explanation
A. Patients with PKD may have issues with kidney function over time, which can affect potassium levels. Typically, a high-potassium diet is not recommended for those with kidney problems because it can exacerbate hyperkalemia.
B. Polycystic kidney disease can lead to progressive loss of kidney function, and many patients eventually require dialysis or a kidney transplant as the disease advances and kidney function declines.
C. There is no general recommendation for a vasectomy solely based on having PKD. While PKD is a genetic condition, and individuals with PKD can pass the condition on to their children, there is no requirement for men with PKD to undergo sterilization.
D. People with PKD are potential candidates for kidney transplantation if their kidney function deteriorates to the point where dialysis is required. PKD itself does not disqualify individuals from receiving a kidney transplant.
Correct Answer is A
Explanation
A. Hematocrit measures the proportion of blood volume that is occupied by red blood cells. Epoetin alfa stimulates red blood cell production, so a therapeutic effect would be indicated by an increase in hematocrit levels. This is a key laboratory result to monitor when assessing the effectiveness of epoetin alfa in treating anemia in CKD patients.
B. Serum potassium levels are important to monitor in CKD patients due to the risk of hyperkalemia, but they are not directly affected by epoetin alfa. Decreasing serum potassium is not a primary indicator of the therapeutic effect of epoetin alfa.
C. Platelet count measures the number of platelets in the blood, which are crucial for blood clotting. Epoetin alfa is not designed to affect platelet counts; thus, a change in platelet count is not an indicator of the medication's therapeutic effect.
D. White blood cell count reflects the immune system's status and is not directly influenced by epoetin alfa. This medication specifically targets red blood cell production and does not impact white blood cell counts.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.